Maravai Q3 2022 Earnings Report
Key Takeaways
Maravai LifeSciences reported a revenue of $191.3 million for Q3 2022, with a net income of $99.7 million and Adjusted EBITDA margins of 69%. The revenue includes $16.4 million from Biologics Safety Testing, $48.4 million from Nucleic Acid Production base business, and $126.5 million from COVID-19 related CleanCap® revenue.
Total revenues reached $191.3 million.
Net income was $99.7 million.
Adjusted EBITDA margins were 69%.
Expanded mRNA raw material offering with GMP-grade N1-Methyl-Pseudouridine-5’-Triphosphate.
Maravai
Maravai
Maravai Revenue by Segment
Forward Guidance
Total revenue for 2022 is projected to be in the range of $880.0 million to $890.0 million, reflecting overall year-over-year growth of 10% to 11%. Adjusted EBITDA (non-GAAP) is now expected to be in the range of $650.0 million to $660.0 million. Adjusted fully diluted EPS (non-GAAP) is now expected to be in the range of $1.76 - $1.80 per share.
Revenue & Expenses
Visualization of income flow from segment revenue to net income